CHSI Catalyst Health Solutions, (MM)

Catalyst Health Solutions, Inc. (NASDAQ: CHSI), a pharmacy benefit management (PBM) company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.

“We are pleased with our second quarter financial performance and the Company's continued execution of its strategic plans. Key client renewals, new sales and the significant transaction with Independence Blue Cross position the Company for long-term continued growth,” stated David T. Blair, Chief Executive Officer of Catalyst.

This year the Company has successfully renewed key customer relationships including the State of Mississippi and School Employees' Health Plan which covers 190,000 members, the State of Louisiana Office of Group Benefits which covers 225,000 members, the Hotel Employees and Restaurant Employees International Union (H.E.R.E.I.U)/Culinary Health Fund which covers 185,000 participants and Delhaize America which covers Food Lion’s 55,000 members and Hannaford Bros. Co.’s 20,000 members.

Additionally, Catalyst has secured new PBM business consisting of self-funded employers, unions and health plans which cumulatively represent more than $250 million in annualized revenues. “Clearly, 2010 is shaping up to be another strong year for new business,” said Blair.

The Company’s generic dispensing rate increased 4 percentage points from the second quarter of 2009 to its current rate of 71%. “Our clinically focused approach increases generic utilization, a key driver of margin growth through aligned incentives with our clients,” added Blair.

Acquisition of FutureScripts

Catalyst also announced that it has signed a definitive agreement to acquire Independence Blue Cross’ (IBC) FutureScripts subsidiaries for $225 million in cash. FutureScripts provides Catalyst with additional meaningful scale, delivering PBM services to approximately 1 million lives and managing over 14 million prescriptions annually. Following the closing of the FutureScripts acquisition, Catalyst will manage IBC’s pharmacy benefits under the terms of a new 10-year contract. IBC is a leading health insurer in southeastern Pennsylvania. IBC and its affiliates provide coverage to nearly 3.3 million people.

“This transaction between Catalyst and IBC creates a uniquely aligned relationship that will drive improved outcomes and lower healthcare costs for IBC’s clients and members,” commented Blair. “The alliance once again validates Catalyst’s client-centric value proposition.”

The transaction is expected to close in 2010, subject to customary closing conditions and the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Credit Facility

The Company has also entered into a new five-year $350 million senior credit facility with a lending group led by SunTrust Robinson Humphrey, Inc., as Administrative Agent. The new senior credit facility is comprised of a $200 million revolving credit facility and a $150 million term loan. This new senior credit facility replaces the Company's previous $100 million secured revolving credit facility.

Hai Tran, Chief Financial Officer of Catalyst, commented, "We appreciate the support of the strong group of banking partners and believe the commitment of these banks is a testament to the Company's historical performance as well as its future prospects. The new credit facility will provide us with additional financial capacity as we execute on our strategic plans."

2010 Financial Guidance

The Company’s previously stated earnings guidance for 2010 was $1.80 to $1.88 per diluted share. Transaction expenses and financing costs related to the acquisition of FutureScripts and the new credit facility are expected to be $0.06 per diluted share in the second half of 2010. As a result, management now expects 2010 earnings to be at the low end of its guidance range. Management confirms the Company is tracking towards its previously stated 2010 revenue guidance of $3.3 billion to $3.6 billion. The 2010 financial guidance excludes FutureScripts results after the transaction closes.

Second Quarter Results

Revenue for the second quarter increased by $172.5 million, or 24%, to $890.1 million from $717.6 million in the prior year’s comparable quarter. The increase in revenue is due to the increase in prescription volume and price inflation on brand drugs, offset by the impact of the increase in generic utilization. Total unadjusted claims processed in the second quarter increased to 16.4 million from 13.9 million for the same period in 2009. The increase in prescription volume was primarily due to the addition of new clients. Generic utilization increased to 71% from 67% in the second quarter of 2009.

Adjusting for the difference in days supply between mail-order and retail, total prescription volume was 17.8 million, an increase of 2.9 million, or 20%, compared to 14.9 million in the prior year. Adjusted mail order prescription volume was 2.2 million for the second quarter, a 45% increase over the 1.5 million adjusted mail order prescriptions in the prior year.

Gross profit for the second quarter increased $10.6 million, to $55.7 million, or 6.3% of revenue, compared to $45.1 million, or 6.3% of revenue, in the second quarter of the prior year. The increase in gross profit is primarily due to the increase in revenue, the realization of the economics of our mail service pharmacy, higher generic utilization, the contribution of performance management fees, enhanced drug manufacturer rebates, improved pharmacy reimbursement rates and higher formulary compliance.

Second quarter operating income increased 22% to $31.6 million from $25.9 million in the second quarter of 2009. The increase in operating income was primarily due to the increase in gross profit, offset by a $4.8 million increase in selling, general and administrative expenses. The increase in selling, general and administrative expenses was primarily associated with initiatives to support the Company’s continued growth, such as additional employee, facilities and vendor costs.

Net income for the second quarter of 2010 was $19.5 million, or $0.44 per diluted share, compared to the prior year’s net income of $16.2 million, or $0.37 per diluted share.

Six Months Results

Revenue for the six months ended June 30, 2010 increased 21%, to approximately $1.7 billion from $1.4 billion in the prior year. The increase in revenue is due to the increase in prescription volume and price inflation on brand drugs, offset by the impact of the increase in generic utilization. Total unadjusted claims processed increased to 32.5 million for the six months ended June 30, 2010 from 27.7 million for the same period in 2009. The increase in prescription volume was primarily due to the addition of new clients.

Adjusting for the difference in days supply between mail-order and retail, total prescription volume was 35.4 million, an increase of 5.7 million, or 19%, compared to 29.7 million in the prior year. Adjusted mail order prescription volume was 4.3 million for the first six months of 2010, a 41% increase over the 3.1 million adjusted mail order prescriptions in the prior year.

Gross profit for the first six months of 2010, increased by $20.1 million to $106.4 million, or 6.2% of revenue, compared to $86.3 million, or 6.1% of revenue, in the first six months of the prior year. The increase in gross profit is primarily due to the increase in revenue, the realization of the economics of our mail service pharmacy, higher generic utilization, the contribution of performance management fees, enhanced drug manufacturer rebates, improved pharmacy reimbursement rates and higher formulary compliance.

Operating income increased by $12.4 million to $60.1 million in the first six months of 2010 from $47.7 million in the same period of the prior year. The increase in operating income was primarily due to the increase in gross profit offset by a $7.7 million increase in selling, general and administrative expenses. The increase in selling, general and administrative expenses was primarily associated with initiatives to support the Company’s continued growth, such as additional employee, facilities and vendor costs.

Net income for the first six months of 2010 was $36.9 million, or $0.83 per diluted share, compared to $30.0 million, or $0.69 per diluted share, in the prior year.

About Catalyst Health Solutions, Inc. (www.chsi.com):

Catalyst Health Solutions, Inc. is built on strong, innovative principles in the management of prescription drug benefits and provides an unbiased, client-centered philosophy resulting in industry-leading client retention rates. The Company's subsidiaries include Catalyst Rx, a full-service pharmacy benefit manager serving more than 7 million lives in the United States and Puerto Rico; HospiScript Services, LLC, one of the largest providers of pharmacy benefit management services to the hospice industry; and Immediate Pharmaceutical Services, Inc., a fully-integrated prescription mail service facility in Avon Lake, Ohio. The Company's clients include self-insured employers including state and local governments, managed care organizations, unions, hospices, third-party administrators and individuals.

This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties that might materially affect our results, particularly those risks referred to in our Annual Report on Form 10-K for the year ended December 31, 2009 under “Item 1A. Risk Factors.” Readers are urged to carefully review and consider the various disclosures made in our Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission that attempt to advise interested parties of the risks and uncertainties that may affect our business. Catalyst Health Solutions, Inc. does not undertake any obligation to update forward-looking statements, whether as a result of new information, future events, or other developments.

    CATALYST HEALTH SOLUTIONS, INC. and Subsidiaries   CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited)   For the three months For the six months ended June 30, ended June 30, 2010   2009 2010   2009 Revenue (excludes member co-payments of $231,174, $189,878, $485,377 and $392,303 for the three months and six months ended June 30, 2010 and 2009, respectively) $ 890,107 $ 717,629 $ 1,722,419 $ 1,420,901 Direct expenses 834,383 672,494 1,616,048 1,334,636 Selling, general and administrative expenses   24,083   19,262   46,292   38,581 Total operating expenses   858,466   691,756   1,662,340   1,373,217 Operating income 31,641 25,873 60,079 47,684 Interest income (expense), net   (117)   160   (274)   353 Income before income taxes 31,524 26,033 59,805 48,037 Income tax expense   12,045   9,876   22,905   18,062 Net income $ 19,479 $ 16,157 $ 36,900 $ 29,975   Net income per share, basic $ 0.44 $ 0.38 $ 0.84 $ 0.70 Net income per share, diluted $ 0.44 $ 0.37 $ 0.83 $ 0.69 Weighted average shares of common stock outstanding, basic 43,846 43,039 43,735 42,987 Weighted average shares of common stock outstanding, diluted 44,521 43,770 44,463 43,697     CATALYST HEALTH SOLUTIONS, INC. and Subsidiaries   CONSOLIDATED SELECTED INFORMATION (In thousands) (Unaudited)   For the three months For the six months ended June 30, ended June 30, 2010   2009 2010   2009 Retail prescriptions 15,619 13,368 31,064 26,632 Total mail prescriptions 740 512 1,440 1,019 Total prescriptions 16,359 13,880 32,504 27,651 Total adjusted prescriptions(1) 17,839 14,904 35,384 29,689  

Adjusted mail order penetration %(2)

12% 10% 12% 10% Generic utilization % 71% 67% 70% 67%  

Gross profit

55,724 45,135 106,371 86,265 Operating income 31,641 25,873 60,079 47,684 Depreciation & amortization 3,268 2,834 6,381 5,579  

(1) Adjusted prescription volume equals the number of mail-order prescriptions multiplied by 3, plus retail prescriptions. Mail-order prescriptions are multiplied by 3 to adjust for the fact that they include approximately 3 times the number of product days supplied compared with retail prescriptions.

(2) The percentage of adjusted mail-order prescriptions to total adjusted prescriptions.